The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.

"Declarations Ethics approval and consent to participateAML patient samples were obtained from The Ohio State University Comprehensive Cancer Center Leukemia Tissue Bank under an Institutional Review Board-approved protocol with informed consent according to the Declaration of Helsinki. Animal studies were carried out under protocols approved by the Ohio State University Institutional Animal Care and Use Committee. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by a Conquer Cancer Foundation Young Investigator Award (NRG), an American Cancer Society Clinician Scientist Development Grant (NRG), the OSU Comprehensive Cancer Center, and the D. Warren Brown Foundation (JAW). The OSU Comprehensive Cancer Center Leukemia Tissue Bank patient sample procurement and storage was supported by the National Cancer Institute (NCIP30CA016058)."